CONCEPT MAP -PSYCHOPHARMACOLOGY SCAVENGER HUNT CONCEPT MAP

WK2Assgn George D - Concept Map for

Psychopharmacologic Approaches to Treatment of Psychopathology (Approaches to Treatment) (Walden University)

Scan to open on Studocu

Studocu is not sponsored or endorsed by any college or university

WK2Assgn George D - Concept Map for

Psychopharmacologic Approaches to Treatment of Psychopathology (Approaches to Treatment) (Walden University)

Scan to open on Studocu

Studocu is not sponsored or endorsed by any college or university Downloaded by tina snow ([email protected])

lOMoARcPSD|50318221

1

Downloaded by tina snow ([email protected])

lOMoARcPSD|50318221

2

PSYCHOPHARMACOLOGY SCAVENGER HUNT CONCEPT MAP

high affinity for the receptor binds to and activates receptors of Blocks binding of certain receptors binds to the same receptor as an lower potency than agonist on cells agonist preventing biological response stabilize the inactive conformation of the receptor. Once bound to the receptor, Competes with the agonist and antagonist. Have affinity but zero intrinsic Produce a pharmacological effect opposite to Efficacy that of an agonist Induces a conformational change. Submaximal response Antagonist Medications Negative intrinsic efficacy

Response like or mimics the Partial Medications Naloxone Inverse agonist medications natural ligand of the receptor Brexpiprazole Arpiprazole Competitive Weaker Competitive Haloperidol Antagonist antagonist activation of intracellular signaling 5 HT1A / 5 HT2A 5 HT1A Bind D2 receptor pathways. μ opioid receptor κ and δ opioid receptors Affinity and intrinsic efficacy Alters Serotonin increases serotonin decrease basal signaling of receptor Agonist Medications transmission transmission 1. Displaces opioid molecules Inhibiting activity reduction in dopaminergic neurotransmission D2 receptor D2 receptor 2. Treat Opioid overdose

Oxycodone Amphetamine Alters Dopamine Stabilize dopamine Risperidone Treat mood disorders (such as schizophrenia, Neurotransmission levels schizoaffective disorders 5-HT2A receptors and D2 receptors. Antidepressant effects lower psychotic Acts on mu amine-associated receptor 1 symptoms Blocks Serotonin and Dopamine receptor Pimavanserin (TAAR1) receptor Produces: Treats schizophrenia, bipolar disorder, Acts on 5-HT2A receptor 1. Analgesia 1. Increases Dopamine and autism-related irritability. 2. Euphoria 2. releases the release of modulates serotonin signaling 3. Respiratory norepinephrine depression 3. Increased levels of these Treat Parkinsons-related neurotransmitters Psychosis

Agonist

Spectrum

Agonist Partial Antagonist Inverse Agonist

Downloaded by tina snow ([email protected])

lOMoARcPSD|50318221

3

References

Berg, K., & Clarke, W. (2018). Making sense of pharmacology: Inverse agonism and functional

selectivity. International Journal of Neuropsychopharmacology, 21(10), 962–977.

HYPERLINK "https://doi.org/10.1093/ijnp/pyy071"https://doi.org/10.1093/ijnp/pyy071

Kikuchi, T., Maeda, K., Suzuki, M., Hirose, T., Futamura, T., & McQuade, R. D. (2021).

Discovery research and development history of the dopamine d2 receptor partial agonists,

aripiprazole and brexpiprazole. Neuropsychopharmacology Reports, 41(2), 134–143.

HYPERLINK "https://doi.org/10.1002/npr2.12180"https://doi.org/10.1002/npr2.12180

Nasseef, T., Singh, J., Ehrlich, A., McNicholas, M., Park, D., Ma, W., Kulkarni, P., Kieffer, B.,

& Darcq, E. (2019). Oxycodone-mediated activation of the mu opioid receptor reduces

whole brain functional connectivity in mice. ACS Pharmacology & Translational

Science, 2(4), 264–274. HYPERLINK

"https://doi.org/10.1021/acsptsci.9b00021"https://doi.org/10.1021/acsptsci.9b00021

Peris, L., & Szerman, N. (2021). Partial agonists and dual disorders: Focus on dual

schizophrenia. Frontiers in Psychiatry, 12. HYPERLINK

"https://doi.org/10.3389/fpsyt.2021.769623"https://doi.org/10.3389/fpsyt.2021.769623

Reddy, H., Poole, J., Maguire, G., & Stahl, S. (2020). New medications for neuropsychiatric

disorders. Psychiatric Clinics of North America, 43(2), 399–413. HYPERLINK

"https://doi.org/10.1016/j.psc.2020.02.008"https://doi.org/10.1016/j.psc.2020.02.008

Schardt, J., Jhajj, H., O'Meara, R., Lwo, T., Smith, M., & Tessier, P. (2022). Agonist antibody

discovery: Experimental, computational, and rational engineering approaches. Drug

Discovery Today, 27(1), 31–48. HYPERLINK

Downloaded by tina snow ([email protected])

lOMoARcPSD|50318221

4

"https://doi.org/10.1016/j.drudis.2021.09.008"https://doi.org/10.1016/

j.drudis.2021.09.008

Trøstheim, M., Eikemo, M., Haaker, J., Frost, J., & Leknes, S. (2022). Opioid antagonism in

humans: A primer on optimal dose and timing for central mu-opioid receptor blockade.

Neuropsychopharmacology, 48(2), 299–307. HYPERLINK

"https://doi.org/10.1038/s41386-022-01416-z"https://doi.org/10.1038/s41386-022-01416-

z

Underhill, S., Hullihen, P., Chen, J., Fenollar-Ferrer, C., Rizzo, M., Ingram, S., & Amara, S.

(2019). Amphetamines signal through intracellular taar1 receptors coupled to gα13 and

gαs in discrete subcellular domains. Molecular Psychiatry, 26(4), 1208–1223.

HYPERLINK "https://doi.org/10.1038/s41380-019-0469-2"https://doi.org/10.1038/

s41380-019-0469-2

Downloaded by tina snow ([email protected])

lOMoARcPSD|50318221